Overview

Sensory and Opioid Mechanisms of Affective Touch

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
0
Participant gender:
All
Summary
Background: Medicines called opioids are used to treat pain. The body also produces opioids. These are called endorphins. Researchers want to learn more about how these natural opioids work. This might lead to new therapies for conditions like depression, anxiety, and chronic pain. Objective: To determine how opioids affect how pleasant or unpleasant it feels when the skin is touched, compressed, or heated. Eligibility: Healthy right-handed adults ages 18-50. Design: Participants will be screened under another protocol. Participants will have 2 study visits with the same procedures, at least 1 day apart. Each visit will last 3-4 hours. Participants will wear shorts or change into scrubs so researchers can test on their legs. Participants will answer questions and have urine tests. Participants will have a brain magnetic resonance imaging (MRI) scan. The scanner is a metal cylinder in a strong magnetic field. Participants will lie on a table that slides in and out of the cylinder. A device called a coil will be placed over the head. During MRI, participants will have sensory testing. They will get several types of touch to the calf of the leg. These include gentle brushing of the skin, gentle compression of the calf with an inflation sleeve, and heat stimuli. Participants will have an intravenous line placed each day. They will get naloxone 1 day and saline the other day. Participants will not be told which they get. Naloxone is a drug that blocks opioid receptors. The MRI and sensory testing will then be repeated. After each stimuli block, participants will rate the sensations as well as their mood and calmness/anxiety.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Treatments:
Naloxone
Criteria
-INCLUSION CRITERIA:

All subjects must be:

- Between 18 and 50 years old.

- Right-handed (on Edinburgh Handedness Inventory).

- Fluent in English.

- Able to provide written informed consent.

EXCLUSION CRITERIA:

Overall exclusion criteria for the study:

- Unable to comply with study procedures (or does not rate stimuli as tolerable) or
unable to schedule visits promptly (including inability to schedule the second session
within approximately 14 days of the first session)

- Pregnancy or breastfeeding.

- Use of recreational drugs in the past month (e.g., marijuana,
methylenedioxymethamphetamine (MDMA, 'ecstasy' or 'Molly'), Lysergic acid diethylamide
(LSD), cocaine, methamphetamine, heroin, prescription and/or opioids).

- Congenital lower limb deficiency or amputation.

- Peripheral neuropathy, dermatological condition such as scars or burns, or has had a
tattoo in the testing region within the previous four weeks that might influence
cutaneous sensibility.

- Women who consume more than 7 alcoholic beverages per week, and men who consume more
than 14 drinks per week.

- Current chronic pain condition or has had chronic pain in the past year (painful
condition lasting more than six months), including ongoing treatment with medications
for neuropathic pain (e.g. gabapentin, tricyclic antidepressants, pregabalin,
tramadol)

- Major medical condition, such as kidney, liver, cardiovascular (including blood clots,
hypertension, preexisting cardiac arrhythmia), autonomic, pulmonary, or neurological
problems (e.g., seizure disorder ) or a chronic systemic disease (e.g., diabetes).

- Current diagnosis or pharmacological treatment of psychiatric disorders such as major
depression, major anxiety-related problems, post-traumatic stress syndrome, bipolar
disorder, psychosis, attention-deficit/hyperactivity disorder or current or lifetime
alcohol or substance abuse disorders (as identified in study #16-AT-0077)

- Participant has metal in his/her body which would make having an MRI scan unsafe, such
as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal
pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye
liner or small metal fragments in the eye that welders and other metal workers may
have.

- Participant is uncomfortable in small closed spaces (has claustrophobia) so that
he/she would feel uncomfortable in the MRI machine or cannot lie comfortably flat on
his/her back for up to 75 minutes in the MRI scanner.

- Participants weighs more than 550 lbs.

- Participant has taken any pain medication other than an over-the-counter NSAIDs or
acetaminophen within the last month or for more than one month on a continual basis
within last six months.

- Previous participation in 13-AT-0143 (related study).

- NIH employees who are subordinates, relatives, or co-workers of the investigators, or
NCCIH Division of Intramural Research (DIR) employees.

- Participants using medications that play into opioid pathways (e.g. loperamide or
dextromethorphan), that could potentially interact with naloxone (naltrexone,
methylnaltrexone, droperidol, fenfluramine and clonidine)

- Participant using any herbal supplements (such as yohimbine) due to risk of unknown
dangerous interaction as there is no data for herbal preparations and naloxone.

- Participant has allergies to naloxone or similar drugs.

EXCLUSION CRITERIA FOR INIDIVIDUAL STUDY SESSION:

- Has consumed alcohol within 24 hours, shows signs of alcohol withdrawal syndrome, or
has behavioral signs of intoxication will be excluded immediately and not have the
possibility to reschedule their session.

- Used topical pain-relieving creams in the testing area (e.g. methylsalicylate,
capsaicin) within 24 hours of testing or used non-steroidal anti-inflammatory drugs
(NSAIDS, e.g. aspirin, ibuprofen), acetaminophen, or naproxen within 3 days of
testing*.

- To be determined during the pre-session screening. Participants who cannot
refrain from these activities may have their session rescheduled up to two times.
If the participant is found non-compliant during the second rescheduled
appointment, he or she will be excluded from the study.